We report a rare case of the coexistence of a gastric small cell neuroendocrine carcinoma with a gastric adenocarcinoma. A 62-year-old man presented with epigastric soreness for 1 month. Esophagogastroduodenoscopy revealed a Borrmann type I tumor at the lesser curvature of the lower body of the stomach. The patient underwent a distal gastrectomy with D2 lymph node dissection and the resected specimen exhibited a 3.5x3.5 cm sized, fungating lesion. Two separated, not intermingling, lesions with non-adenocarcinoma components encircled by well differentiated adenocarcinoma components were identified microscopically. The non-adenocarcinoma component showed neuroendocrine features, such as a solid and trabecular pattern, and the tumor cells showed a high nuclear grade with minimal cytoplasm, indistinct nucleoli, and positive response for synaptophysin, CD56. The final pathological diagnosis was a gastric mixed exocrine-endocrine carcinoma (MEEC) composed of an adenocarcinoma and small cell neuroendocrine carcinoma of the collision type.
Introduction
The term "mixed exocrine-endocrine carcinoma" (MEEC), which is proposed by the World Health Organization (WHO) classification of endocrine tumors, refers to the neoplasm with divergent exocrine and endocrine differentiation, especially originated in the pancreas, appendix or stomach.(1) Theses tumors were called by different names according to both the extent and the structural shape of two components: composite glandular-endocrine carcinoma, collision tumor, neuroendocrine differentiated adenocarcinoma, amphicrine tumor, goblet cell carcinoid and so on.
Nearly all neoplasms that develop in the stomach are adenocarcinomas, whereas gastric neuroendocrine tumors (NETs) represent less than 1% of all gastric neoplasms. In addition, they account for only 2~4% of all gastrointestinal NETs.(2) Most commonly, NETs are located at the appendix, ileum, or rectum, where NETs occasionally coexist with adenocarcinoma. However, in the stomach, the coexistence of NETSs and adenocarcinoma is rare, and most tumors that do coexist are composed of carcinoid or low-grade Bcell lymphoma and adenocarcinoma. (3, 4) We report here a case of MEEC with adenocarcinoma and small cell neuroendocrine carcinoma.
Case Report
A 62-year-old man presented with epigastric soreness for 1 month. Physical examination was unremarkable and laboratory findings showed no abnormalities. Esophagogastroduodenoscopy revealed a Borrmann type I tumor at the lesser curvature of the lower body of the stomach. Contrast-enhanced computed tomography (CT) showed a 3 cm sized, elevated mass with regional enlarged lymph nodes. The diagnosis, proven from the biopsy specimens taken from the gastric tumor lesion, was poorly differentiated carcinoma. The patient underwent distal gastrectomy with Billroth II anastomosis and D2 lymph node dissection. The resected specimen exhibited a 3.5×3.5 cm sized, Borrmann type I lesion at the body of the stomach macroscopically (Fig. 1) . Microscopically, routine hematoxylin-eosin-stained section showed two separated, not intermingling, lesions with different histologic features under low-power magnification ( Fig. 2A) . These lesions had a characteristic feature with non-adenocarcinoma components encircled by well differentiated adenocarcinoma components ( The most commonly used chemotherapeutic combination regimens for GI EPSCC are cisplatin/etoposide, carboplatin/etoposide, and cisplatin/irinotecan.
In the present case, although the patient underwent curative surgery and was diagnosed with limited disease (TNM stage IB), the tumor consisted of poorly differentiated (small cell) neuroendocrine carcinoma and well differentiated tubular adenocarcinoma, as a collision type. Therefore, we are planning a close follow up strategy keeping in mind the poor prognosis of small cell carcinoma, and the possibility of potential hepatic metastasis. However, after discussing with medical oncologists, we decided to defer adjuvant chemotherapy considering the early stage of the tumor.
